TCGA-O2-A52V-01A-31R-A262-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.420
- G2M_CHECKPOINT+0.380
- E2F_TARGETS+0.350
- HEDGEHOG_SIGNALING+0.340
- APICAL_SURFACE+0.330
- MITOTIC_SPINDLE+0.330
- CHOLESTEROL_HOMEOSTASIS+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- GLYCOLYSIS+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.390
- INTERFERON_ALPHA_RESPONSE-0.310
- INTERFERON_GAMMA_RESPONSE-0.180
- ALLOGRAFT_REJECTION-0.170
- COAGULATION-0.150
- TGF_BETA_SIGNALING-0.090
- COMPLEMENT-0.080
- HEME_METABOLISM-0.070
- ADIPOGENESIS-0.060
- XENOBIOTIC_METABOLISM-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2742-01A-01R-0980-07 | — | cohortSQ1 | 0.805 |
| 2 | SRR17866829 | — | — | 0.779 |
| 3 | TCGA-FD-A3B5-01A-11R-A20F-07 | — | — | 0.769 |
| 4 | ERR2278879 | — | — | 0.760 |
| 5 | MDT-AP-0007 | Med | Medulloblastoma | 0.760 |
| 6 | TCGA-85-7844-01A-11R-2125-07 | — | cohortSQ2 | 0.758 |
| 7 | TCGA-85-7843-01A-11R-2125-07 | — | cohortSQ1 | 0.754 |
| 8 | TCGA-43-6770-01A-11R-1820-07 | — | cohortSQ2 | 0.737 |
| 9 | MNG471 | — | — | 0.736 |
| 10 | C3L-00568 | — | cohortSQ2 | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |